Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Novacyt ( (FR:ALNOV) ) just unveiled an announcement.
Novacyt announced its monthly update on the Liquidity Agreement with Invest Securities SA, detailing the trading of ordinary shares from September 1 to September 30, 2025. During this period, 16,600 shares were purchased and 18,216 shares were sold, with the total number of shares held in treasury at 104,912. The total voting rights stand at 70,626,248 shares, which shareholders can use to determine their interest in the company. The Liquidity Agreement, governed by French law, allows Invest Securities to purchase shares on behalf of Novacyt, with shareholder approval granted for purchases up to €5.00 per share.
More about Novacyt
Novacyt is an international molecular diagnostics company that offers a wide range of integrated technologies and services, focusing primarily on genomic medicine. The company develops, manufactures, and commercializes molecular assays and instrumentation across sectors such as human health, animal health, and environmental. It operates in three business segments: Clinical, Instrumentation, and Research Use Only, and has a commercial presence in over 65 countries.
For a thorough assessment of ALNOV stock, go to TipRanks’ Stock Analysis page.